HA, a biodegradable, biocompatible and non-immunogenic glycosaminoglycan, can work as a targeting moiety for cancer therapy because many types of tumour cells over-express HA receptors like CD44, RHAMM (receptor for hyaluronan-mediated motility, CD168, involved in wound healing and cancer), and HARE (HA receptor for endocytosis). This evidence concerns the gene HMMR and neoplasm.